CA2748942A1 - Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components - Google Patents

Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components Download PDF

Info

Publication number
CA2748942A1
CA2748942A1 CA2748942A CA2748942A CA2748942A1 CA 2748942 A1 CA2748942 A1 CA 2748942A1 CA 2748942 A CA2748942 A CA 2748942A CA 2748942 A CA2748942 A CA 2748942A CA 2748942 A1 CA2748942 A1 CA 2748942A1
Authority
CA
Canada
Prior art keywords
platycodon grandiflorum
extract
hcv
pharmaceutical composition
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2748942A
Other languages
English (en)
French (fr)
Inventor
Jong Woo Kim
Sang Wook Lee
Sang Jin Park
Jung Cheul Shin
Jae Won Yang
Jong Hwan Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
B&C Biopharm Co Ltd
Original Assignee
B&C Biopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B&C Biopharm Co Ltd filed Critical B&C Biopharm Co Ltd
Publication of CA2748942A1 publication Critical patent/CA2748942A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G23/00—Compounds of titanium
    • C01G23/04—Oxides; Hydroxides
    • C01G23/047—Titanium dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F10/00—Individual photovoltaic cells, e.g. solar cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental & Geological Engineering (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA2748942A 2009-01-23 2010-01-21 Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components Abandoned CA2748942A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2009-0006078 2009-01-23
KR20090006078 2009-01-23
KR10-2009-0100092 2009-10-21
KR1020090100092A KR101162710B1 (ko) 2009-01-23 2009-10-21 도라지 추출물 또는 도라지 사포닌 화합물을 함유하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물
PCT/KR2010/000376 WO2010085091A2 (en) 2009-01-23 2010-01-21 Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components

Publications (1)

Publication Number Publication Date
CA2748942A1 true CA2748942A1 (en) 2010-07-29

Family

ID=42753875

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2748942A Abandoned CA2748942A1 (en) 2009-01-23 2010-01-21 Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components

Country Status (8)

Country Link
US (1) US20110274656A1 (enExample)
EP (1) EP2389185A2 (enExample)
JP (1) JP2012515773A (enExample)
KR (1) KR101162710B1 (enExample)
CN (1) CN102264378A (enExample)
AU (1) AU2010207093A1 (enExample)
CA (1) CA2748942A1 (enExample)
WO (1) WO2010085091A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101251589B1 (ko) * 2012-09-27 2013-04-08 한국화학연구원 도라지 또는 도라지 추출물로부터의 순도 및 유효 사포닌 함량이 증가된 조사포닌 조성물의 제조방법
CN103768078B (zh) * 2012-10-22 2019-02-05 北京大学 三萜衍生物及其抗流感用途
KR101475630B1 (ko) 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
WO2014193088A1 (ko) * 2013-05-31 2014-12-04 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
JP6095591B2 (ja) * 2014-02-12 2017-03-15 株式会社アンチエイジング・プロ 山芋抽出物の製造方法
KR101705545B1 (ko) 2015-02-06 2017-02-13 주식회사 웰파이토 도라지 발효물을 유효성분으로 포함하는 기관지질환, 면역증강 및 항비만 예방 효능의 건강차 조성물
KR101880934B1 (ko) 2017-09-14 2018-07-23 주식회사 아오스 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법
WO2020085799A1 (ko) * 2018-10-23 2020-04-30 주식회사 온사이언스 도라지 사포닌을 포함하는 표준화된 도라지 추출물 또는 막분리 도라지 사포닌 추출물을 함유하는 간질환의 예방 또는 치료용 약학적 조성물 및 간기능 개선용 건강기능식품
CN111394266B (zh) * 2019-12-03 2023-12-22 延边大学 一种去芹糖桔梗皂苷d的制备方法及其应用
CN110754573A (zh) * 2019-12-04 2020-02-07 金陵科技学院 一种桔梗皂苷d饲料添加剂及其应用、制备方法
CN113116912A (zh) * 2021-06-07 2021-07-16 长春中医药大学 去芹糖桔梗皂苷d在制备预防和/或治疗肝癌药物中的应用
KR102611611B1 (ko) 2023-03-21 2023-12-11 주식회사 아오스 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849282A (en) * 1990-05-09 1998-12-15 Otsuka Pharmaceutical Co., Ltd. Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
US5405837A (en) * 1993-05-18 1995-04-11 Indiana University Foundation Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
KR20050021026A (ko) 2001-06-15 2005-03-07 주식회사 장생도라지 장생도라지 추출물을 포함하는 면역계의 이상으로부터발생하는 질병의 예방 및 치료용 약제학적 조성물
KR20030021072A (ko) * 2001-09-05 2003-03-12 주식회사 장생도라지 간 질병의 예방 및 치료용 간장질환용제
CN1397560A (zh) * 2002-08-13 2003-02-19 吉林天药科技股份有限公司 从桔梗中提取桔梗总皂苷和单体桔梗皂苷d的方法及其医药新用途和中药制剂
CN1566137A (zh) * 2003-07-04 2005-01-19 深圳亿胜医药科技发展有限公司 桔梗总皂苷生产工艺
KR100564927B1 (ko) * 2003-09-04 2006-03-30 비타민하우스알앤비티(주) 플라티코딘을 유효성분으로 함유하는 항암제
KR100643877B1 (ko) * 2004-07-19 2006-11-10 주식회사 장생도라지 장생도라지 추출물을 유효성분으로 함유하는 알코올성간질환의 억제, 치료용 약학적 조성물 및 알코올대사촉진용 조성물
WO2006046674A1 (ja) * 2004-10-25 2006-05-04 Chugai Seiyaku Kabushiki Kaisha Ｃ型肝炎ウイルス感染症の予防および治療剤
KR20050043880A (ko) * 2005-04-27 2005-05-11 김성호 간염억제활성을 갖는 생약 제제 추출물
KR100543354B1 (ko) * 2005-05-17 2006-01-20 김성호 간염억제활성을 갖는 생약재 추출물
JP4794944B2 (ja) * 2005-08-11 2011-10-19 博光 熊田 Ｃ型肝炎に対するインターフェロン／リバビリン併用療法の有効性の判定方法
CN100406467C (zh) * 2006-05-24 2008-07-30 浙江大学 利用弱极性大孔树脂制备桔梗总皂苷提取物的方法及用途
CN101240005A (zh) * 2007-10-29 2008-08-13 吉林农业大学 一种从桔梗中制备桔梗皂苷d的方法及其在抗癌药物中的应用

Also Published As

Publication number Publication date
KR20100086923A (ko) 2010-08-02
WO2010085091A2 (en) 2010-07-29
AU2010207093A1 (en) 2011-07-21
JP2012515773A (ja) 2012-07-12
KR101162710B1 (ko) 2012-07-05
CN102264378A (zh) 2011-11-30
US20110274656A1 (en) 2011-11-10
WO2010085091A3 (en) 2010-11-25
EP2389185A2 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
US20110274656A1 (en) Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components
Zhang et al. Astragali radix (Huangqi): A time-honored nourishing herbal medicine
Wu et al. In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik
EP3973965A1 (en) Medical use of pentacyclic triterpenoid saponin compound and pharmaceutical composition thereof
KR102459500B1 (ko) 퀘르세틴 배당체를 함유하는 근위축 억제제
Kim et al. Protective effect of linarin against D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure
WO2010111935A1 (zh) 一种新的丹酚酸化合物l、其制备方法和用途
Yang et al. Hepatoprotective and inhibiting HBV effects of polysaccharides from roots of Sophora flavescens
CA2747996C (en) Compounds and methods for enhancing erythropoiesis
Cao et al. Ginkgo biloba exocarp extracts induces apoptosis in Lewis lung cancer cells involving MAPK signaling pathways
KR20130069430A (ko) 돌외의 지페노사이드 추출물을 포함하는 제2형 당뇨병, 비만 또는 고지혈증의 치료 또는 예방용 조성물
JP5923167B2 (ja) 抗ｂ型肝炎薬の調製のためのアンドログラホリドｃ１５位置換シリーズ誘導体の使用
WO2016043517A1 (ko) 목단피，백지 및 시호의 혼합 추출물 또는 이의 분획물을 유효성분으로 함유하는，신경 퇴행성 질환의 치료 및 예방용 약학적 조성물
JP5038310B2 (ja) 骨疾患の予防及び／又は治療用医薬組成物、その組成物を含有する機能性食品もしくは健康食品、並びにその組成物を有効成分とする医薬製剤
CN100429219C (zh) 一类青葙皂苷类化合物及其在医药领域的应用
CN103880856B (zh) 没药烷型倍半萜类衍生物及其药物组合物和其在制药中的应用
KR102694541B1 (ko) 플로로탄닌을 유효성분으로 포함하는 항바이러스제
CN106928299B (zh) 一类来源于地骨皮的化合物，其制法及在降糖方面的应用
Fu et al. Callistephus A from Callistephus chinensis Nees alleviates concanavalin A-induced immunological liver injury in mice by inhibiting the activation of JAK/STAT1 and MAPK signaling pathways
CN110063960B (zh) 3-氢化松苓酸b氰甲酯的制药用途
WO2006046674A1 (ja) Ｃ型肝炎ウイルス感染症の予防および治療剤
CN101229179A (zh) 含有余甘根苷b的药物组合物及其药物用途
WO2006006750A1 (en) A method for preparing purified extract from wild ginseng showing anticancer activity and the composition comprising the same
CN112920196A (zh) 一类抗肥胖症的瑞香烷型二萜及其应用
Niu et al. Research advances on anticancer effect of licorice

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140121